Rx Drugs Info

cyklokapron (tranexamic acidtablet 
cyklokapron (tranexamic acidinjection, solution 
[Pharmacia and Upjohn Company]

Antifibrinolytic agent

DESCRIPTION

Each tablet contains 500 mg of tranexamic acid.

Each mL of the sterile solution for intravenous injection contains 100 mg tranexamic acid and Water for Injection to 1 mL.

FORMULATION

Chemical Name: trans-4-(aminomethyl) cyclohexanecarboxylic acid.

Structural Formula:

Image from Drug Label Content

Tranexamic acid is a white crystalline powder. Inert ingredients in the tablets are microcrystalline cellulose, talc, magnesium stearate, silicon dioxide and povidone.

The aqueous solution for injection has a pH of 6.5 to 8.0.

CLINICAL PHARMACOLOGY

Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid.

Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro.

Tranexamic acid in concentrations up to 10 mg per mL blood has no influence on the platelet count, the coagulation time or various coagulation factors in whole blood or citrated blood from normal subjects. On the other hand, tranexamic acid in concentrations of 10 mg and 1 mg per mL blood prolongs the thrombin time.

The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen. Tranexamic acid does not bind to serum albumin.

Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.

After an intravenous dose of 1 g , the plasma concentration time curve shows a triexponential decay with a half-life of about 2 hours for the terminal elimination phase. The initial volume of distribution is about 9 to 12 liters. Urinary excretion is the main route of elimination via glomerular filtration. Overall renal clearance is equal to overall plasma clearance (110 to 116 mL/min) and more than 95% of the dose is excreted in the urine as the unchanged drug. Excretion of tranexamic acid is about 90% at 24 hours after intravenous administration of 10 mg per kg body weight. After oral administration of 10 to 15 mg per kg body weight, the cumulative urinary excretion at 24 hours is 39% and at 48 hours, 41% of the ingested dose or 78% and 82% of the absorbed material. Only a small fraction of the drug is metabolized. After oral administration, 1% of the dicarboxylic acid and 0.5% of the acetylated compound are excreted.

The plasma peak level after 1 g orally is 8 mg per L and after 2 g, 15 mg per L, both obtained three hours after dosing.

An antifibrinolytic concentration of tranexamic acid remains in different tissues for about 17 hours, and in the serum, up to seven or eight hours.

Tranexamic acid passes through the placenta. The concentration in cord blood after an intravenous injection of 10 mg per kg to pregnant women is about 30 mg per L, as high as in the maternal blood. Tranexamic acid diffuses rapidly into joint fluid and the synovial membrane. In the joint fluid the same concentration is obtained as in the serum. The biological half-life of tranexamic acid in the joint fluid is about three hours.

The concentration of tranexamic acid in a number of other tissues is lower than in blood. In breast milk the concentration is about one hundredth of the serum peak concentration. Tranexamic acid concentration in cerebrospinal fluid is about one tenth of that of the plasma. The drug passes into the aqueous humor, the concentration being about one tenth of the plasma concentration.

Tranexamic acid has been detected in semen where it inhibits fibrinolytic activity but does not influence sperm migration.

INDICATIONS AND USAGE

CYKLOKAPRON Tablets and Injection are indicated in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.

CONTRAINDICATIONS

CYKLOKAPRON Tablets and Injection are contraindicated:

  1. In patients with acquired defective color vision, since this prohibits measuring one endpoint that should be followed as a measure of toxicity (see WARNINGS).
  2. In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by CYKLOKAPRON in such patients.
  3. In patients with active intravascular clotting.

WARNINGS

Focal areas of retinal degeneration have developed in cats, dogs and rats following oral or intravenous tranexamic acid at doses between 250 to 1600 mg/kg/day (6 to 40 times the recommended usual human dose) from 6 days to 1 year. The incidence of such lesions has varied from 25% to 100% of animals treated and was dose-related. At lower doses some lesions have appeared to be reversible.

Limited data in cats and rabbits showed retinal changes in some animals with doses as low as 126 mg/kg/day (only about 3 times the recommended human dose) administered for several days to two weeks.

No retinal changes have been reported or noted in eye examinations in patients treated with tranexamic acid for weeks to months in clinical trials.

However, visual abnormalities, often poorly characterized, represent the most frequently reported postmarketing adverse reaction in Sweden. For patients who are to be treated continually for longer than several days, an ophthalmological examination, including visual acuity, color vision, eye-ground and visual fields, is advised, before commencing and at regular intervals during the course of treatment. Tranexamic acid should be discontinued if changes in examination results are found.

PRECAUTIONS

General

The dose of CYKLOKAPRON Tablets and Injection should be reduced in patients with renal insufficiency because of the risk of accumulation. (See DOSAGE AND ADMINISTRATION.)

Ureteral obstruction due to clot formation in patients with upper urinary tract bleeding has been reported in patients treated with CYKLOKAPRON.

Venous and arterial thrombosis or thromboembolism has been reported in patients treated with CYKLOKAPRON. In addition, cases of central retinal artery and central retinal vein obstruction have been reported.

Patients with a previous history of thromboembolic disease may be at increased risk for venous or arterial thrombosis.

CYKLOKAPRON should not be administered concomitantly with Factor IX Complex concentrates or Anti-inhibitor Coagulant concentrates, as the risk of thrombosis may be increased.

Patients with disseminated intravascular coagulation (DIC), who require treatment with CYKLOKAPRON, must be under strict supervision of a physician experienced in treating this disorder.

Carcinogenesis, Mutagenesis, Impairment Of Fertility

An increased incidence of leukemia in male mice receiving tranexamic acid in food at a concentration of 4.8% (equivalent to doses as high as 5 g/kg/day) may have been related to treatment. Female mice were not included in this experiment.

Hyperplasia of the biliary tract and cholangioma and adenocarcinoma of the intrahepatic biliary system have been reported in one strain of rats after dietary administration of doses exceeding the maximum tolerated dose for 22 months. Hyperplastic, but not neoplastic, lesions were reported at lower doses. Subsequent long term dietary administration studies in a different strain of rat, each with an exposure level equal to the maximum level employed in the earlier experiment, have failed to show such hyperplastic / neoplastic changes in the liver. No mutagenic activity has been demonstrated in several in vitro and in vivo test systems.

Pregnancy (Category B)

Reproduction studies performed in mice, rats, and rabbits have not revealed any evidence of impaired fertility or adverse effects on the fetus due to tranexamic acid.

There are no adequate and well-controlled studies in pregnant women. However, tranexamic acid is known to pass the placenta and appears in cord blood at concentrations approximately equal to maternal concentration. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Labor And Delivery

See above under Pregnancy.

Nursing Mothers

Tranexamic acid is present in the mother's milk at a concentration of about a hundredth of the corresponding serum levels. Caution should be exercised when CYKLOKAPRON is administered to a nursing woman.

Pediatric Use

The drug has had limited use in pediatric patients, principally in connection with tooth extraction. The limited data suggest that dosing instructions for adults can be used for pediatric patients needing CYKLOKAPRON therapy.

Geriatric Use

Clinical studies of CYKLOKAPRON did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

ADVERSE REACTIONS

Gastrointestinal disturbances (nausea, vomiting, diarrhea) may occur but disappear when the dosage is reduced. Giddiness and hypotension have been reported occasionally. Hypotension has been observed when intravenous injection is too rapid. To avoid this response, the solution should not be injected more rapidly than 1 mL per minute. This adverse reaction has not been reported with oral administration.

Worldwide Postmarketing Reports

Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, and central retinal artery and vein obstruction) have been rarely reported in patients receiving tranexamic acid for indications other than hemorrhage prevention in patients with hemophilia. However, due to the spontaneous nature of the reporting of medical events and the lack of controls, the actual incidence and causal relationship of drug and event cannot be determined.

OVERDOSAGE

There is no known case of overdosage of CYKLOKAPRON Tablets and Injection. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.

DOSAGE AND ADMINISTRATION

Immediately before dental extraction in patients with hemophilia, administer 10 mg per kg body weight of CYKLOKAPRON intravenously together with replacement therapy (see PRECAUTIONS). Following surgery, a dose of 25 mg per kg body weight may be given orally three or four times daily for 2 to 8 days.

Alternatively, tranexamic acid can be administered entirely orally, 25 mg per kg body weight 3 to 4 times a day beginning one day prior to surgery.

Parenteral therapy, 10 mg per kg body weight 3 to 4 times daily can be used for patients unable to take oral medication.

Note: For patients with moderate to severe impaired renal function, the following dosages are recommended:

Tranexamic Acid Dosage
Serum Creatinine (µmol/L) I.V. Dosage Tablets
120 to 250 (1.36 to 2.83 mg/dL) 10 mg/kg BID 15 mg/kg BID
250 to 500 (2.83 to 5.66 mg/dL) 10 mg/kg daily 15 mg/kg daily
>500 (>5.66 mg/dL) 10 mg/kg every 48 hours or 5 mg/kg every 24 hours 15 mg/kg every 48 hours or 7.5 mg/kg every 24 hours

For intravenous infusion, CYKLOKAPRON Injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions and Dextran solutions. The mixture should be prepared the same day the solution is to be used. Heparin may be added to CYKLOKAPRON Injection. CYKLOKAPRON Injection should NOT be mixed with blood. The drug is a synthetic amino acid, and should NOT be mixed with solutions containing penicillin.

HOW SUPPLIED

CYKLOKAPRON Tablets 500 mg (flat, white, round with beveled edges, arcs above and below the letters CY)

NDC 0013-0114-00 100 tablets.

CYKLOKAPRON Injection 100 mg/mL

NDC 0013-1114-10 10 × 10 mL ampules

STORAGE

Store at 25°C (77°F); excursions permitted to15°-30°C (59°-86°F) [see USP Controlled Room Temperature].

Rx only

Image from Drug Label Content

LAB-0258-2.0

November 2005


Cyklokapron (tranexamic acid)
PRODUCT INFO
Product Code 0013-0114 Dosage Form TABLET
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
tranexamic acid (tranexamic acid) Active 500 MILLIGRAM  In 1 TABLET
microcrystalline cellulose Inactive  
talc Inactive  
magnesium stearate Inactive  
silicon dioxide Inactive  
povidone Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color WHITE (white) Score 1
Shape ROUND (round) Symbol false
Imprint Code CY Coating false
Size 18mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0013-0114-00 100 TABLET In 1 BOTTLE None

Cyklokapron (tranexamic acid)
PRODUCT INFO
Product Code 0013-1114 Dosage Form INJECTION, SOLUTION
Route Of Administration INTRAVENOUS DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
tranexamic acid (tranexamic acid) Active 100 MILLIGRAM  In 1 MILLILITER
water for injection Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0013-1114-10 10 AMPULE In 1 BOX contains a AMPULE
1 100 MILLILITER In 1 AMPULE This package is contained within the BOX (0013-1114-10)

Revised: 01/2006Pharmacia and Upjohn Company

Data are from FDA and U.S. National Library of Medicine.